The Therapeutic Effectiveness of the Coadministration of Weekly Risedronate and Proton Pump Inhibitor in Osteoporosis Treatment

Table 3

The value in BMD, NTX/Cr, BAP, PTH, and the physical parameters.

	BP	BP + PPI
Increase of BMD (mg/cm^3)
6 M	2.9 ± 11.5	7.1 ± 7.5
12 M	6.0 ± 23.2	8.0 ± 12.4
18 M	13.3 ± 9.2	13.0 ± 10.6
24 M	15.2 ± 11.2	17.5 ± 3.6
Decrease of NTX/Cr; (nmolBCE/mmol·Cr)
6 M	24.1 ± 23.0	27.4 ± 18.3
12 M	29.8 ± 20.4	33.1 ± 22.2
18 M	28.5 ± 20.1	34.4 ± 20.0
24 M	40.2 ± 10.2	45.6 ± 20.7
Decrease of BAP (U/L)
6 M	4.9 ± 3.8	4.7 ± 5.7
12 M	6.3 ± 3.5	4.6 ± 7.0
18 M	6.2 ± 4.3	5.8 ± 7.2
24 M	7.0 ± 1.2	6.1 ± 5.6
Increase of PTH; (pg/mL)
6 M	0.9 ± 17.5	2.6 ± 12.1
12 M	3.2 ± 11.1	2.7 ± 10.0
18 M	3.6 ± 6.4	4.3 ± 6.9
24 M	5.3 ± 10.0	5.0 ± 12.4
Improvement of physical functioning
6 M	4.7 ± 6.4	8.7 ± 7.1
12 M	4.0 ± 7.7	11.2 ± 9.4^*
18 M	4.5 ± 7.5	9.9 ± 7.3
24 M	9.4 ± 14.2	10.0 ± 6.5
Improvement of bodily pain
6 M	4.1 ± 10.0	11.9 ± 3.6^*
12 M	4.5 ± 11.1	12.2 ± 12.3^**
18 M	11.6 ± 8.7	12.3 ± 10.3
24 M	13.6 ± 7.0	14.5 ± 9.3

Average ± standard deviation. ^* < 0.05, ^** < 0.01.